Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-23-009929
Filing Date
2023-05-15
Accepted
2023-05-15 16:55:59
Documents
60
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q sngx-20230331x10q.htm   iXBRL 10-Q 1264665
2 EX-31.1 sngx-20230331xex31d1.htm EX-31.1 18444
3 EX-31.2 sngx-20230331xex31d2.htm EX-31.2 18502
4 EX-32.1 sngx-20230331xex32d1.htm EX-32.1 8288
5 EX-32.2 sngx-20230331xex32d2.htm EX-32.2 8776
  Complete submission text file 0001558370-23-009929.txt   5803380

Data Files

Seq Description Document Type Size
6 EX-101.SCH sngx-20230331.xsd EX-101.SCH 41988
7 EX-101.CAL sngx-20230331_cal.xml EX-101.CAL 44146
8 EX-101.DEF sngx-20230331_def.xml EX-101.DEF 183605
9 EX-101.LAB sngx-20230331_lab.xml EX-101.LAB 413539
10 EX-101.PRE sngx-20230331_pre.xml EX-101.PRE 306264
54 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20230331x10q_htm.xml XML 842316
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-14778 | Film No.: 23923813
SIC: 2834 Pharmaceutical Preparations